| Literature DB >> 31561525 |
Muhammad Tahir Khan1, Aman Chandra Kaushik2, Aamer Iqbal Bhatti3, Yu-Juan Zhang4, Shulin Zhang5, Amie Jinghua Wei6, Shaukat Iqbal Malik7, Dong Qing Wei8.
Abstract
Pyrazinamide (PZA) is the only drug for the elimination of latent Mycobacterium tuberculosis (MTB) isolates. However, due to the increased number of PZA-resistance, the chances of the success of global TB elimination seems to be more prolonged. Recently, marine natural products (MNPs) as an anti-TB agent have received much attention, where some compounds extracted from marine sponge, Haliclona sp. exhibited strong activity under aerobic and hypoxic conditions. In this study, we screened articles from 1994 to 2019 related to marine natural products (MNPs) active against latent MTB isolates. The literature was also mined for the major regulators to map them in the form of a pathway under the dormant stage. Five compounds were found to be more suitable that may be applied as an alternative to PZA for the better management of resistance under latent stage. However, the mechanism of actions behind these compounds is largely unknown. Here, we also applied synthetic biology to analyze the major regulatory pathway under latent TB that might be used for the screening of selective inhibitors among marine natural products (MNPs). We identified key regulators of MTB under latent TB through extensive literature mining and mapped them in the form of regulatory pathway, where SigH is negatively regulated by RshA. PknB, RshA, SigH, and RNA polymerase (RNA-pol) are the major regulators involved in MTB survival under latent stage. Further studies are needed to screen MNPs active against the main regulators of dormant MTB isolates. To reduce the PZA resistance burden, understanding the regulatory pathways may help in selective targets of MNPs from marine natural sources.Entities:
Keywords: MTB; PZA; latent TB; marine anti-TB compounds; sponges
Mesh:
Substances:
Year: 2019 PMID: 31561525 PMCID: PMC6836121 DOI: 10.3390/md17100549
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Crystal structures of PZA and POA targets. (A) PZase; (B) RpsA; (C) Domain organization of RpsA and its C-terminal domain (MtRpsACTD); (D) PanD. PZase converts PZA into POA inhibiting the activity of PanD and RpsA. POA interactions with RpsA (E) and PZA with PZase (F). The prodrug PZA is converted into active form, POA, inhibiting the trans-translational proteins (RpsA).
Figure 2Compounds active against latent TB (dormant state). Compound 1, fistularin-3/11-epi-fistularin-3; compound 2, 15-methyl-9(Z)-hexadecenoic acid; compound 3, (hexadecyloxy) propane,1,2-diol; compound 4, 15- alpha methoxypuupehenol; and compound 5, puupehedione. Compound 3 exhibited mild activity against replicating MTB (active TB).
Biological profile of marine pure compounds against dormant MTB isolates adopted from Felix et al; 2017 with permission from 2017 American Society for Microbiology [51].
| Compound | Formula | Molecular Mass (kDa) | MICR | MICD | MICR/MICD | IC50 | SIR c | SID d | Source |
|---|---|---|---|---|---|---|---|---|---|
| 1 | C31H30Br6N4O11 | 1,114.02 | 8.5 | Inactive | NA | 200 | 23.5 | NA | HBOI.047.F07 |
| 2 | C19H40O3 | 316.53 | 60.8 | 22.5 | 2.7 | 200 | 3.3 | 8.5 | HBOI.047.F07 |
| 3 | C16H30O2 | 254.41 | 28.5 | 7.9 | 3.6 | 200 | 7.0 | 31.1 | HBOI.031.C02 |
| 4 | C22H32O4 | 360.49 | 11.3 | 0.5 | 21.8 | 8 | 0.7 | 15.5 | HBOI.050.F04 |
| 5 | C21H26O3 | 326.44 | 87.6 | 15.4 | 5.6 | 50.4 | 0.6 | 6.2 | HBOI.050.F04 |
a MICR, MIC against replicating Mtb-Lux. b MICD, MIC against dormant Mtb-Lux. c SIR, SI for replicating Mtb-Lux. d SID, SI for dormant Mtb-Lux.
Figure 3SigH signaling pathway under stress conditions. (A) The SigH signaling mechanism. (B) Boolean network simulation with the SigH-RshA complex negatively regulated the pathway, deactivating the regulatory pathway. (C) Boolean network simulation without the SigH-RshA complex, where the “SigH-PO4” activates the mechanism. RshA-P: phosphorylated RshA; SigH-PO4: phosphorylated SigH.
Figure 4Anti-TB compounds, C-1 to C-5 active against latent TB. The blue colored lines were the same in all compounds. Haliclonacyclamines A and B (C-1 and C-2). 22-hydroxyhaliclonacyclamine B (C-3), Halicyclamine A (C-4), and neopetrosiamine A (C-5).